GT Biopharma adopts amended bylaws with proxy access and exclusive forum provisions

GT Biopharma, Inc.

Amended bylaws effective Nov 3, 2022 include proxy access for eligible long-term shareholders.
Updated advance notice requirements for director nominations and shareholder proposals.
Added exclusive forum provision for certain legal actions.
Clarified authority to adjourn shareholder meetings when quorum not present.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

GT Biopharma, Inc.: Amended and restated bylaws to update procedures, including shareholder meetings, advance notice requirements, proxy access, and exclusive forum provision (effective 2022-11-03).

Change: bylaw amendment
Effective: 2022-11-03

Exact text from the filing

On November 3, 2022, the Board of Directors of GT Biopharma, Inc. (the “Company”) amended and restated the Company’s Restated Bylaws (the “Amended Bylaws”) to update certain procedures and make various technical and conforming changes.

View on SEC.gov

84 governance changes filed in the last 30 days. Browse all governance changes →

GT Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031139

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.